MC

469.45

+1.68%↑

SANES

9.955

+4.18%↑

SAF

288.7

+3.89%↑

BBVA

18.93

+4.24%↑

BNP

84.88

+3.92%↑

MC

469.45

+1.68%↑

SANES

9.955

+4.18%↑

SAF

288.7

+3.89%↑

BBVA

18.93

+4.24%↑

BNP

84.88

+3.92%↑

MC

469.45

+1.68%↑

SANES

9.955

+4.18%↑

SAF

288.7

+3.89%↑

BBVA

18.93

+4.24%↑

BNP

84.88

+3.92%↑

MC

469.45

+1.68%↑

SANES

9.955

+4.18%↑

SAF

288.7

+3.89%↑

BBVA

18.93

+4.24%↑

BNP

84.88

+3.92%↑

MC

469.45

+1.68%↑

SANES

9.955

+4.18%↑

SAF

288.7

+3.89%↑

BBVA

18.93

+4.24%↑

BNP

84.88

+3.92%↑

Search

IPSOS

Open

BrancheFinanzen

34.28 1.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

33.42

Max

34.44

Schlüsselkennzahlen

By Trading Economics

Einkommen

107M

133M

Verkäufe

792M

1.4B

KGV

Branchendurchschnitt

7.934

54.484

Dividendenrendite

5.96

Gewinnspanne

9.737

Angestellte

20,000

EBITDA

194M

261M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+55.37% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

5.96%

4.92%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

146M

1.5B

Vorheriger Eröffnungskurs

33.16

Vorheriger Schlusskurs

34.28

Nachrichtenstimmung

By Acuity

49%

51%

167 / 441 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

IPSOS Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Nike, RH, NCino

31. März 2026, 22:35 UTC

Ergebnisse

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. Apr. 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. März 2026, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. März 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. März 2026, 23:33 UTC

Market Talk
Wichtige Nachrichtenereignisse

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. März 2026, 23:21 UTC

Ergebnisse

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. März 2026, 23:14 UTC

Market Talk
Ergebnisse

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. März 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss Widens >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. März 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. März 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. März 2026, 21:33 UTC

Ergebnisse

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. März 2026, 21:32 UTC

Ergebnisse

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. März 2026, 21:28 UTC

Ergebnisse

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. März 2026, 21:26 UTC

Ergebnisse

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. März 2026, 21:25 UTC

Ergebnisse

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. März 2026, 21:24 UTC

Market Talk
Ergebnisse

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. März 2026, 21:22 UTC

Ergebnisse

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. März 2026, 21:22 UTC

Ergebnisse

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. März 2026, 21:21 UTC

Ergebnisse

Nike's Digital Channel Still Too Promotional, CFO Says

31. März 2026, 21:20 UTC

Ergebnisse

Nike CEO: Converse Remains Important to Portfolio

Peer-Vergleich

Kursveränderung

IPSOS Prognose

Kursziel

By TipRanks

55.37% Vorteil

12-Monats-Prognose

Durchschnitt 53.23 EUR  55.37%

Hoch 72 EUR

Tief 36.7 EUR

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für IPSOS – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

39.72 / 43Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

167 / 441 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über IPSOS

Ipsos SA, through its subsidiaries, provides survey-based research services for companies and institutions in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company offers services in the information production and analysis chain, including data collection, data processing and integration, data analysis, information delivery and presentation, and information activation. It also provides audience measurement, automotive and mobility development, brand health tracking, channel performance, corporate reputation, creative excellence, customer experience, healthcare, innovation, Ipsos MMA, Ipsos UU, market strategy and understanding, observer, public affairs, social intelligence analytics, and other specialist services, as well as research methodologies, such as device agnosticism, programmatic sampling, and digital face-to-face interview. In addition, the company offers online and mobile integrated services and device agnostic solutions that include online surveys adapted to laptops, smartphones, and tablets; and qualitative research services, as well as operates Ipsos.Digital, a do-it-yourself platform. Further, it provides artificial intelligence and data science solutions that develops and provides analytical tools based on data science, machine learning, big analytics, and modelling; and behavioral science and neuroscience solutions, as well as operates Ipsos Knowledge Centre for teams and clients. Ipsos SA was incorporated in 1975 and is headquartered in Paris, France.
help-icon Live chat